Nuzyra Side Effects

Generic name: omadacycline

Medically reviewed by Drugs.com. Last updated on Jul 10, 2024.

Note: This document provides detailed information about Nuzyra Side Effects associated with omadacycline. Some dosage forms listed on this page may not apply specifically to the brand name Nuzyra.

Applies to omadacycline: oral tablet.

Other dosage forms:

• intravenous powder for solution

Precautions

It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly. Blood and urine tests may be needed to check for unwanted effects.

If your symptoms do not improve within a few days, or if they become worse, check with your doctor.

Using this medicine while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant. If you think you have become pregnant while using this medicine, tell your doctor right away.

This medicine may cause serious allergic reactions, which can be life-threatening and require immediate medical attention. Tell your doctor right away if you have a rash, itching, hoarseness, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth after using this medicine.

Omadacycline may cause diarrhea, and in some cases it can be severe. It may occur 2 months or more after you Stop taking omadacycline (the active ingredient contained in Nuzyra) Do not take any medicine to treat diarrhea without first checking with your doctor. Diarrhea medicines may make the diarrhea worse or make it last longer. If you have any questions about this or if mild diarrhea continues or gets worse, check with your doctor.

This medicine may cause intracranial hypertension (increased pressure in the head). Tell your doctor right away if you have a headache, blurred vision, or other change in vision.

Omadacycline may cause your skin to be more sensitive to sunlight than it is normally. Exposure to sunlight, even for short periods of time, may cause skin rash, itching, redness or other discoloration of the skin, or a severe sunburn. When you begin taking this medicine:

• Stay out of direct sunlight, especially between the hours of 10:00 a.m. and 3:00 p.m., if possible.
• Wear protective clothing, including a hat. Also, wear sunglasses.
• Apply a sunblock product that has a sun protection factor (SPF) number of at least 15. Some patients may require a product with a higher SPF number, especially if they have a fair complexion. If you have any questions about this, check with your doctor.
• Apply a sunblock lipstick that has an SPF of at least 15 to protect your lips.
• Do not use a sun lamp or tanning bed or booth.

If you have a severe reaction from the sun, check with your doctor right away.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Common side effects of Nuzyra

Some side effects of omadacycline may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Serious side effects of Nuzyra

Along with its needed effects, omadacycline may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking omadacycline:

For healthcare professionals

Applies to omadacycline: intravenous powder for injection, oral tablet.

General adverse events

In the community-acquired bacterial pneumonia clinical trial, serious side effects were reported in 6% of patients treated with this drug and 6.7% of patients treated with moxifloxacin; therapy was discontinued due to any side effect in 5.5% of patients treated with this drug and 7% of patients treated with moxifloxacin. In the pooled acute bacterial skin and skin structure infection trials, serious side effects were reported in 2.3% of patients treated with this drug and 1.9% of patients treated with comparator; therapy was discontinued due to side effects in 1.7% of patients treated with this drug and 1.5% of patients treated with comparator.^[Ref]

Gastrointestinal

• Very common (10% or more): Nausea (up to 30%), vomiting (up to 17%)
• Common (1% to 10%): Diarrhea, constipation
• Frequency not reported: Abdominal pain, dyspepsia, oral candidiasis, increased lipase^[Ref]

Local

• Common (1% to 10%): Infusion site reactions (infusion site extravasation, pain, erythema, swelling, inflammation, irritation, peripheral swelling, skin induration)^[Ref]

Hepatic

• Common (1% to 10%): Increased ALT, increased AST, increased GGT
• Frequency not reported: Increased bilirubin^[Ref]

Cardiovascular

• Common (1% to 10%): Hypertension
• Frequency not reported: Tachycardia, atrial fibrillation^[Ref]

Nervous system

• Common (1% to 10%): Headache
• Frequency not reported: Dysgeusia, lethargy, vertigo^[Ref]

Psychiatric

• Common (1% to 10%): Insomnia^[Ref]

Other

• Common (1% to 10%): Death
• Frequency not reported: Fatigue, increased alkaline phosphatase, mortality imbalance^[Ref]

In the community-acquired bacterial pneumonia clinical trial, mortality imbalance was observed with 8 deaths (2%) in patients treated with this drug compared to 4 deaths (1%) in patients treated with moxifloxacin. All deaths (both treatment groups) occurred in patients older than 65 years; most patients had multiple comorbidities. Causes of death varied and included worsening and/or complications of infection and underlying conditions. The cause of the mortality imbalance has not been established.

In acute bacterial skin and skin structure infection trials, 1 death (0.1%) was reported in patients treated with this drug and 3 deaths (0.4%) were reported in patients treated with linezolid.^[Ref]

Hematologic

• Frequency not reported: Anemia, thrombocytosis^[Ref]

Hypersensitivity

• Frequency not reported: Hypersensitivity^[Ref]

Dermatologic

• Frequency not reported: Pruritus, erythema, hyperhidrosis, urticaria^[Ref]

Respiratory

• Frequency not reported: Oropharyngeal pain^[Ref]

Musculoskeletal

• Frequency not reported: Increased creatine phosphokinase^[Ref]

Genitourinary

• Frequency not reported: Vulvovaginal mycotic infection^[Ref]

See also:

Frequently asked questions

• What type of drug is Nuzyra (omadacycline)?

Further information

Nuzyra side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer